B
ICPT

Baird’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Baird’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$1.7M Buy
6,032
+339
+6% +$73.4K 0.02% 587
2014
Q4 		$888K Buy
+5,693
New +$1.05M 0.01% 765

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baird's ICPT Position: Q1 2015 in Review

Baird increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 6% in Q1 2015, buying an estimated $73.4K and bringing the position to 6,032 shares worth $1.7M. The position accounts for 0.02% of the portfolio, ranked #587.

Baird first reported a position in ICPT in Q4 2014 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold ICPT as of Q1 2015.

  • Baird held 6,032 shares of Intercept Pharmaceuticals, Inc. worth $1.7M as of Q1 2015.
  • Baird bought 339 Intercept Pharmaceuticals, Inc. shares in Q1 2015, an estimated $73.4K.
  • Intercept Pharmaceuticals, Inc. made up 0.02% of Baird's portfolio in Q1 2015, its #587 holding.
  • Baird first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and has held it in 2 quarters since.
  • 200 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.